Physician profile
Bruce Maniet
NPI 1568449825
$8,720.08
in general payments reported to CMS, 2019-2025
34 companies · $721 in 2025
The $721 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,006 · 2020: $1,255 · 2021: $1,818 · 2022: $619 · 2023: $960 · 2024: $1,340 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,021.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,059.78 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $1,122.38 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $878.04 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $764.94 | 2019-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $577.38 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $560.29 | 2019-2022 | |
| Lilly USA, LLC | $429.52 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $402.55 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $238.48 | 2023-2025 | Rexulti |
| Eisai INC. | $221.54 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $184.33 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $155.18 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $124.88 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.07 | 2019-2020 | |
| Heartflow, INC. | $106.69 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $100.60 | 2020-2021 | |
| Bioventus LLC | $100.39 | 2020-2024 | Durolane, Supartz Fx Sodium Hyaluronate |
| Pfizer INC. | $96.65 | 2019-2022 | |
| Axsome Therapeutics, INC. | $60.75 | 2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $58.76 | 2020-2022 | |
| Scpharmaceuticals INC. | $53.87 | 2025 | |
| Dexcom, INC. | $43.72 | 2024-2025 | Dexcom G6 Transmitter |
| Corium, LLC | $36.40 | 2023 | Adlarity |
| Cmp Pharma, INC. | $33.29 | 2021 | |
| Glaxosmithkline, LLC. | $32.20 | 2024 | Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $22.59 | 2021 | |
| Organon LLC | $21.99 | 2025 | Nexplanon |
| Sk Life Science, INC. | $21.64 | 2024 | |
| Medtronic, INC. | $19.63 | 2025 | Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.46 | 2024 | Trulance, Xifaxan |
| Exact Sciences Corporation | $18.14 | 2024 | Cologuard Collection Kit |
| Axonics, INC. | $17.88 | 2023 | Axonics |
| Gilead Sciences, INC. | $13.52 | 2019 | |
| Assertio Therapeutics, INC. | $12.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Maniet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.